Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

CMA investigation into lithium based medicines

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “We note the announcement from the CMA but it would be inappropriate to comment on the specifics of an on-going investigation into lithium based medicines. However, we have consistently stated that we will condemn any action which would artificially manipulate or raise prices where there are no clear patient benefits or supply issues. In our experience, generic firms faced with difficult commercial decisions or where prices become unsustainably low will take into account their own market share and act responsibly so any decisions do not adversely put patient access at risk.”